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Abstract
Introduction: The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prog-
nostic and Natural History Study (PNHS) aims at understanding the role of amy-
loid imaging in the earliest stages of Alzheimer’s disease (AD). AMYPAD PNHS adds
(semi-)quantitative amyloid PET imaging to several European parent cohorts (PCs) to
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predict AD-related progression as well as address methodological challenges in amy-
loid PET.
Methods: AMYPAD PNHS is an open-label, prospective, multi-center, cohort study
recruiting from multiple PCs. Around 2000 participants will undergo baseline amyloid
positron emission tomography (PET), half ofwhomwill be invited for a follow-upPET12
at least 12months later.
Results: Primary include several amyloid PET measurements (Centiloid, SUVr, BPND,
R1), and secondary are their changes frombaseline, relationship to other amyloidmark-
ers (cerebrospinal fluid and visual assessment), and predictive value of AD-related
decline.
Expected Impact: Determining the role of amyloid PET for the understanding of this
complex disease and potentially improving secondary prevention trials.
K EYWORD S
amyloid, positron emission tomography imaging, preclinical and prodromal Alzheimer’s disease,
secondary prevention
1 BACKGROUND
Recent years have seen massive effort into improving the understand-
ing of the pathogenesis and trajectory of Alzheimer’s disease (AD)
in its preclinical stages. Currently, AD dementia is conceptualized as
the endpoint of a cascade of events leading to cognitive impairment,
with the accumulation of amyloid beta (A𝛽) plaques being considered
the first detectable change in the brain—a process that continues for
decades prior to the onset of cognitive decline.1 Although no causal
link between A𝛽 plaque deposition and subsequent dementia has been
established, it remains a pathological hallmark in the pathway toward
AD dementia. As such, its measurement has been part of many obser-
vational studies in aging and dementia, and it has also been used in clin-
ical trials both as inclusion criteria and as part of theoutcomemeasures
in the case of anti-amyloid interventions.
Although no disease-modifying therapy has been approved yet,
promising signals have been observed in a number of anti-amyloid clin-
ical trials, in which small to modest reductions in brain amyloid levels
were achieved in treatment groups, albeit not accompanied by effects
on cognitive decline.2-6 These trials havemaintainedhope in the search
for a successful therapy, but also identified challenges in trial design.
These include potentially starting interventions too late in the dis-
ease course, suboptimal inclusion criteria, insufficient drug dosage, and
incorrect treatment target, also questioning the validity of the widely
accepted amyloid cascade hypothesis.7 Nonetheless, recent studies in
cognitively normal subjects suggest that the amyloid hypothesis might
still hold at stages at which A𝛽 is driving the cascade, that is, before
widespread and irreversible neuronal damage is present.8-11
Considering its placement in the cascade of events and the recent
focus on the earlier stages of AD, accurately determining the pres-
ence of A𝛽 pathology and understanding its role in the development
of dementia is relevant not only for etiological diagnosis, but also for
monitoring disease progression, and in trials of secondary prevention.
Currently, the presence of A𝛽 pathology can be determined either by
cerebrospinal fluid (CSF), positronemission tomography (PET) imaging,
or recently also by blood samples.12,13 While prescribed for the same
goal, a non-negligible proportion of patients can present with discor-
dant results between CSF and PET.14 CSF is considered to indicate the
presenceof amyloid pathology in its earliest stages, but it plateaus rela-
tively early in the ADdisease course, while amyloid PET imaging shows
continued build-up of amyloid burden beyond the CSF plateau15 and it
provides information on the spatial distribution of the pathology in the
brain.
Despite such promising characteristics, amyloid PET imaging may
not have been used to its full potential previously, and there are a num-
ber of knowledge gaps that have not yet been fully addressed in the
early stages of AD. For example, recent developments in AD research
indicate visual assessment and/or global semi-quantitative measures
such as the Standard Uptake Value ratio (SUVR) might not be opti-
mally suited for tracking disease progression and for some clinical trial
applications.16,17 More specifically, global SUVR has been shown to
detect the presence of A𝛽 plaques at a generally later stage of pathol-
ogy, indicating it might not be appropriate for capturing amyloidosis
in the preclinical stages at which pathology might still be restricted
to specific brain regions.18,19 Visual assessment might in turn be able
to capture focal signal, but it lacks the quantitative aspect necessary
for accurately measuring longitudinal change and treatment effects.
Further, both metrics are less specific than quantitative measure-
ments of plaque density available from dynamic PET scans and poten-
tially suffer from bias such as those introduced by changes in blood
flow.1720 Therefore, determining the optimal methodology for amy-
loid PET analysis becomes increasingly relevant moving forward to
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understand disease progression and support both current and future
AD trials.21,22
The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD)
Prognostic and Natural History Study (PNHS) has been established to
collect amyloid PET scans in a large-scale population in the early stages
of AD. This collection will allow the assessment of the true potential
of amyloid PET imaging as a tool for visualizing and quantifying both
the natural disease progression and eventual effects of anti-amyloid
interventions. Toefficiently achieve its goals, this studywasestablished
within an intrinsically collaborative framework, providing European
cohorts of preclinical and prodromal individuals with access to amyloid
PET imaging to complement their efforts in creating well-phenotyped
cohorts. This collaborative effort allows us to complement risk predic-
tion models and enables future disease-modifying trials by providing
relevant insight into the optimal use of amyloid PET imaging in an early
population at a large scale.23
2 METHODS
2.1 The Amyloid Imaging to Prevent Alzheimer’s
Disease (AMYPAD) Consortium
The AMYPADConsortiumwas initiated inOctober 2016 as a key com-
ponent of the InnovativeMedicine Initiative (IMI)-Alzheimer’s Disease
platform,24 and receives the support from the European Union’s Hori-
zon 2020 research and innovation program and from the European
Federation of Pharmaceutical Industries and Associations (EFPIA).
Partners include academia, EFPIA, and small and medium-sized enter-
prises (SMEs) such as IXICO and SYNAPSE.
One of two clinical trials from the Consortium, the AMYPAD PNHS
is sponsored by the UMC Amsterdam location VUmc (VUmc) and the
scientific leadership is shared between the Barcelona 𝛽 Brain Research
Center (BBRC) and Janssen Pharmaceutica. In addition, partner sites
include the University of Edinburgh, University of Geneva, Karolinska
Institutet Stockholm, and the Central Hospital University of Toulouse,
and several non-partner sites are also engaged.
2.2 Parent cohorts
AMYPAD PNHS recruits from various parent cohorts (PCs) of similar
characteristics. The PCs are all European, actively enrolling or per-
forming follow-up visits, and focused on pre-dementia subjects. In
addition, information on cognitive functioning (eg, clinical diagnosis
or neuropsychological assessments), disease biomarkers (eg, CSF or
magnetic resonance imaging [MRI] measures), and traditional risk
factors (eg, genetic and environmental) is available within each PC.
These characteristics are essential, as the study is set to efficiently
complement ongoing efforts from all individual PCs by providing
access to amyloid PET as an early biomarker, while being granted
access to additional variables to model cross-biomarker relationships
and their effects on disease progression.
RESEARCH INCONTEXT
Systematic review: Recent Alzheimer’s disease (AD) sec-
ondary prevention trials highlight the need for understand-
ing the disease pathogenesis and trajectory. Althoughmany
studies use positron emission tomography (PET) to assess
amyloid pathology, the technique’s potential in obtaining
quantitative and topographical assessment is generally not
yet fully explored in research and clinical trials. The Amy-
loid Imaging to Prevent Alzheimer’s Disease Prognostic
and Natural History Study (AMYPAD PNHS) is designed to
determine amyloid PET imaging’s role in assessing AD risk
in pre-dementia subjects.
Interpretation: Amyloid PET scans will be performed at a
large scale in collaboration with several well-characterized
longitudinal European cohorts to determine the added
value of amyloid PET imaging to determineAD risk in a pre-
dementia population, over and above widely available AD
biomarkers.
Future directions: The knowledge gained within AMYPAD
PNHS can be used to determine the value and best prac-
tices in amyloid PET imaging both in research and sec-
ondary prevention trials, improving inclusion criteria and
measurements of treatment effects.
The main and original PC is European Prevention of Alzheimer’s
Dementia (EPAD) due to the inherent collaborative framework
between the two IMI projects.23 As of October 2019, two additional
PCs have been formally included inAMYPADPNHS. These are the Pre-
clinAD EMIF-AD cohort in Amsterdam25 and a subset of the ALFA+
cohort in Barcelona.26 As the inclusion of PCs is an ongoing and
dynamic process and additional cohorts are still under consideration,
an up-to-date overview of collaborating PCs and their details will be
made available on the AMYPADwebsite https://amypad.eu/data.
2.3 Target population
AMYPAD PNHS aims to recruit up to 2000 subjects, who must be
coming from one of the selected PCs, aged 50 years or older, and not
demented. In addition, the inclusion and exclusion criteria of a particu-
larPC indirectly apply toPNHS, and the complete information for these
will also be available on the website.
Recruitment is aimed at subjects at the beginning of the amyloid
cascade, where emerging pathology is traditionally undetected by
established standards. More specifically, the goal is to enroll not only
amyloid-positive participants, but also those with negative amyloid
PET scans, as well as those in a so-called gray zone of amyloid burden
(eg, participants with ambiguous or discordant CSF and PET amy-
loid status or on the verge of CSF or PET biomarker abnormality). The
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F IGURE 1 Schematic representation of Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic andNatural History Study
(PNHS) design and its relationship with ongoing parent cohorts
cohort balancewill be constantlymonitored andmanaged, dynamically
adapting participant selection criteria when needed.
2.4 Participant selection and the adaptive algorithm
approach
To ensure enrollment of the target population, the process of selecting
eligible participants from PCsmakes use of an innovative and adaptive
approach that considersmultiple dimensions to better identify the tar-
get population, avoiding simple single-biomarker cut-offs. This is made
possible due to the access AMYPAD PNHS has to information on indi-
vidual risk profiles available from PCs. Whenever available, previous
information on amyloid status (either from an earlier amyloid PET scan
or fromCSFmeasurements) will be themain determinant for inclusion.
In addition, a combination of age, family history, genetic profile, and
other well-established risk factors will also be considered.
The selection algorithms, customized for each PC, are determined
andappliedbyanestablished selection and feasibility committee (SFC),
with representatives from the project leadership independent from
site activities. This ensures blinding to traceable individual participant
information and limits potential bias across all studies.
2.5 Study timelines and design
The AMYPAD PNHS is a prospective, multi-center, pan-European, lon-
gitudinal cohort study linked to several ongoing European PCs. Par-
ticipants recruited into PNHS will continue their participation in their
respective PC and undergo amyloid PET imaging in addition to the pro-
cedures of the parent study. Recruitment started in late 2018 and is
expected to continue until late 2021.
Participants can enter the AMYPAD PNHS at any point in their
participation in their PC, and the alignment between AMYPAD and
PC visits is strongly encouraged for efficiency and temporal corre-
spondence between biomarker assessments (Figure 1). Once part of
AMYPADPNHS, participants can undergo either a standard static PET
imaging session or a dual-window quantitative dynamic PET imaging
acquisition protocol.27
After at least 12 months, ≈50% of participants will be invited for
a follow-up scan, to be performed using the same acquisition proto-
col as baseline. All participants undergoing dynamic baseline PET will
be invited for follow-up, while results from baseline static PET scans
will be provided to the SFC so that a follow-up algorithm can select the
right participants for follow-up scanning. As some PCs have performed
amyloid PET prior to this study, these historical data sets will be made
available to AMYPAD, enabling direct longitudinal assessment of amy-
loid accumulation.
2.6 Amyloid PET imaging in AMYPADPNHS
Two radiotracers are available in this study, namely [18F]florbetaben
(NeuraCeq R©) and [18F]flutemetamol (Vizamyl R©) (Figure 2), with both
imaging agents aimed to be equally represented across the study
and acquisition protocols. Taking advantage of the available expertise
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F IGURE 2 Example images of Neuraceq (left) and Vizamyl (right).
Upper images: visually negative amyloid positron emission
tomography (PET) scans showing only tracer retention in white
matter. Lower images: visually positive amyloid PET scans showing
tracer retention also in cortical areas. A, anterior; L, left hemisphere; P,
posterior; R, right hemisphere
within participating centers, AMYPAD aims to perform dynamic acqui-
sitions for as many scans as possible.
2.6.1 Image acquisition
Static scans are acquired according to the standard protocol for each
tracer, starting at 90 minutes post-injection (p.i.) and collected in four
frames of 5 minutes each (90 to 110 minutes p.i.).28,29 In contrast,
dynamic scans are acquired in two parts;27 first, a 30-minute scan is
started at the time of tracer injection (0 to 30 minutes p.i.), then sub-
jects can rest outside the camera for 60 minutes, and finally, the stan-
dard static acquisition is performed for 20 minutes starting at 90 min-
utes p.i. (90 to 110 minutes p.i.). This protocol allows for interleaved
scanning, which translates to efficient scanner use and reduced par-
ticipant burden (Figure 3). For quantification purposes, the closest 3D
T1-weighed (3D T1w) MR scan available from the PCs will be used for
anatomical delineation.
2.6.2 Image analysis
(Semi-)Quantitative analyses will be performed centrally, with the pre-
processing being performed by IXICO, togetherwith the quantification
of the static scans. The additional pharmacokinetic modeling for quan-
tification of the dynamic scans will be performed by VUmc.
IXICO’s pre-processing pipeline uses a subject-specific multi-atlas
structural segmentation approach (LEAP).30 First, the four 5-minute
PET frames are co-registered andaveraged. Then, theMR is segmented
using this LEAP approach and, together with the resulting anatomical
regions of interest (ROIs), it is finally co-registered to the PET. This
allows flexible selection of multiple single and/or composite regions
for the (semi-)quantitative analyses. In addition, PET images will also
be warped into Montreal Neurological Institute (MNI) space to enable
exploratory voxel-wise comparisons.
Once the pre-processing is performed, IXICO’s SUVr and Cen-
tiloid quantification is performed, as the pipeline has been vali-
dated for the computation of Centiloid values to allow for pooled
analyses across tracers.31 Next to IXICO’s quantification and for
those subjects for whom dynamic scans are available, pre-processed
images and corresponding ROIs are transferred to VUmc to undergo
the quantification of non-displaceable binding potential (BPND) val-
ues. For that purpose, both the receptor parametric mapping (RPM)
method32 and the reference model of Logan Graphical Analysis will be
applied.33
For all analyses, four commonly used reference regions (RR) will be
used in this project; namely cerebellar gray matter, whole cerebellum,
pons, and subcortical white matter. The whole cerebellum will be the
RR used for the primary and secondary outcomes of the study because
it is the standard Centiloid RR. All other regions will be explored as
alternatives, and their suitability will be assessed with respect to
SUV stability across individuals, clinical groups, and longitudinally.
Further, comparing these RRs will allow the determination of their
specific statistical power to detect cross-sectional differences in (semi-
)quantitative metrics and/or statistically significant and plausible
longitudinal changes. Therefore, whenever applicable, results with
an alternative and well-suited RR will be reported in addition to the
primary outcomes.
In addition to the (semi-)quantitative analyses, visual interpreta-
tion of PET images will be performed locally using a standardized and
blinded method and following the tracer-specific reader training pro-
vided by Life Molecular Imaging (for [18F]florbetaben/NeuraCeq R©)
and GE Healthcare (for [18F]flutemetamol/Vizamyl R©). The standard
positive/negative assessment will be complemented with regional
visual classification, and the corresponding reader’s confidence (1 to 5)
will be recorded.
3 OBJECTIVES
The primary objective of the study is to (semi-)quantitatively assess
amyloid burden using PET to complement the extensive assessments
of PCs and enable the achievement of secondary objectives. This is
aligned with the fact that AMYPAD PNHS only collects amyloid PET
imaging data, relying on the data available from the PCs to model any
other dimension of a so-called AD risk probability spectrum. This con-
cept aims to assess an individual’s risk of progression to AD dementia
using different dimensions such as cognition, disease biomarkers, and
established genetic and environmental risk factors.23
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F IGURE 3 Example of interleaved dynamic dual-timewindow acquisition protocol. The dual-timewindow protocol allows for interleaved
acquisition, in which the scan of a second subject can be initiated during the break of the first subject
In addition, three groups of secondary objectives are defined. The
first relates to the subset of dynamic and longitudinal amyloid PET
imaging data collected in the study, as well as to the main outcomes of
PCs. Secondary objectives in this group include to quantify (1) relative
cerebral blood flow available from dynamic PET images and (2) amy-
loid plaque accumulation available from longitudinal data. These will
then be used alone and in combination to predict (1) decline in global
measures of cognitive functioning as well as within specific cognitive
domains, and (2) structural and functional brain changes.
The second group was defined to compare techniques for assess-
ing amyloid status in their role and ability to predict cognitive decline.
First, the BPND will be used to assess the validity and possible bias
within the SUVR measurement in those subjects who have dynamic
scans. Next, the relationship between traditional global amyloid PET
measures (Centiloid, SUVR, and BPND), regional level data and avail-
able systems for staging amyloid burden34-36 will be assessed. Finally,
data combined fromAMYPADPNHSandPCswill be used todetermine
the cross-sectional and longitudinal agreement between brain amy-
loid status classificationmethods (PETquantification andvisual assess-
ment, as well as CSF). As a result, the optimal methodology to obtain
(cross-sectional and longitudinal) (semi-)quantitativemeasuresof amy-
loid burden that robustly predict cognitive decline will be determined.
The final groupwill assess the relationship between amyloid burden
and other AD risk factors, as well as their relation to subsequent cogni-
tive decline, potentially informing future interventions targeting such
risk factors.
4 OUTCOME MEASURES
The primary outcome measures in AMYPAD PNHS are (semi-
)quantitative measurements of amyloid burden, namely the SUVR, the
BPND when applicable (for dynamic acquisitions only), and correspond-
ing Centiloid values37 due to the use of different tracers. In addition,
SUV and R1 (a proxy for cerebral blood flow available from dynamic
PET imaging38) will also be estimated for all regions.
Secondary outcome measures include non-amyloid PET variables
already available from the PCs, including measurements of cogni-
tive status, basic and advanced MR sequences, CSF, and risk factors.
Because the measures for global cognition may differ per PC, multi-
ple established and exploratory measures will be considered, such as
theMiniMental State Examination (MMSE), theClinicalDementia Rat-
ing (CDR) scale, or domain-specific and global functioning scores deter-
mined from individual tests. This exploratory harmonization strategy
will leverage the extensive number of distinct neuropsychological tests
available from PCs, which always encompass at least all five commonly
defined cognitive domains.
In addition, MR-based secondary outcome measures will include
traditional measures of gray-matter volume and atrophy rates. When-
ever available, additionalmeasurements fromadvancedMRsequences
will be assessed. At least from EPAD Longitudinal Cohort Study, mea-
sures of white matter integrity, functional and structural connectivity,
aswell as cerebral perfusionwill alsobeavailable for a subset of theMR
imaging data. Details on the complete set of advanced MR sequences
per PCwill be available on the AMYPADwebsite (https://amypad.eu/).
Several CSFmeasurementswill be available for a large subset of the
data, including at least A𝛽42, A𝛽40, t-tau, and p-tau. Finally, traditional
risk factors such as apolipoprotein E (APOE) 𝜀4 status, family history,
hypertension, and diabetes are also collected in most PCs and will be
available for AMYPADPNHS analyses.
5 DATA HARMONIZATION
As a multi-center study, AMYPAD PNHS must ensure optimal data
harmonization in many levels of the data collection process. With
respect to imaging, both the PET acquisition protocols and the core
MR sequence (3D T1w) are the same across centers, and the scanners
are qualified by IXICOprior to study commencement to ensure harmo-
nized data quality. Exceptions to this are scans collected from PCs that
enteredAMYPADPNHSwith historical scans, in which case the histor-
ical protocol is maintained for longitudinal consistency and a posteriori
harmonization is performed.
With respect to the remaining measurements, these will be more
heterogeneous due to the inclusion of multiple PCs. Especially with
respect to cognitive measures, PCs may differ due to distinct goals or
experience with specific assessments. Therefore, the harmonization of
non-imaging data will be a major endeavor in AMYPAD PNHS, which
will leverage the expertise of external partners and collaborators with
previous experience.39 The final strategy for harmonization of each
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variable will be made openly available on AMYPAD’s website, provid-
ing clarity to users and potential support for future initiatives aiming to
perform similar analyses. As an initial step, cognitive assessments will
be analyzed per cognitive domain and z-scored to improve comparison
across tests. A list of original variables available from PCs is available
on the website andwill be updated as new PCs join the project.
6 EXPECTED IMPACT
Although amyloid PET imaging holds great promises for better under-
standing and phenotyping AD at the pre-dementia phase, the current
use of the technique has not led to an effective use of its full poten-
tial in AD research and clinical trials. AMYPAD PNHS will collect amy-
loid PET scans at large scale in a pre-dementia population, creating
the opportunity to address current knowledge gaps and previous chal-
lenges. The study is set in a collaborative framework with established
European cohorts of well-phenotyped individuals, which will allow for
a detailed characterization of the natural history of AD and its early
stages. In addition, AMYPAD PNHS will perform both dynamic and
static scans and (semi-)quantitatively assessing the images beyond
current dichotomized methodologies that disregard the topography
of the pathology. Therefore, by addressing both previously identified
methodological issues and the complexmulti-modal aspects of AD, this
study aims to ultimately identify the role of amyloid PET in AD risk
assessment.
The large-scale (semi-)quantitative amyloid PET data collected in
AMYPADPNHSmay be essential for studying amyloid accumulation in
early populations, in which the pathological signal is often subtle40 and
large sample sizes may be needed. In particular, the study will obtain
results from a head-to-head comparison between BPND and SUVR
across the complete range of amyloid burden, which will help deter-
mine whether and when dynamic scans are required in the context of
ADresearchandpreventive trials.17 This questionwill be answerednot
only in terms of power to detect longitudinal changes and robustness
against physiological confounders, but also with respect to the addi-
tional information available from dynamic PET scans, namely a surro-
gate of cerebral blood flow R1.
38 Although hypoperfusion is a marker
of AD and previous studies have shown strong correlations between
R1, [
18F]FDG and water-PET,41 the value of such information in a pre-
dementia population remains largely unexplored. Such an assessment
can help distinguishing different treatment arms in an anti-amyloid
trial, but it might also serve other therapeutic initiatives, as amyloid
burden can affect several other processes such as synaptic plastic-
ity, mitochondrial function, localized neuro-inflammation, and vascular
health.42
Recent efforts also indicate that the use of amyloid PET can be
further optimized by assessing the available topographical informa-
tion present in PET scans, as well as determining longitudinal rates
of change.22 In fact, regional information from amyloid PET has
been suggested to improve the detection of amyloid pathology in an
asymptomatic population.11,34 Expanding on the concept, a number
of amyloid staging models have been recently developed,34-36 which
could represent powerful tools both for tracking natural disease
progress and supporting trials. These methods identify pathological
signs earlier than conventional dichotomized measures, represent
simple tools for monitoring changes in amyloid burden, and have the
potential to guide trial arm stratification, effectively reducing the
risks of detecting false effects that can be introduced when amyloid
burden is not balanced across treatment arms.16 In this line, AMYPAD
PNHS’s collection of regional visual assessments, reader confidence,
and established and advanced quantification approaches will help
determine the true value of suchmethodologies.
Despite these advances, the large number of failures from anti-
amyloid therapeutic trials have challenged the hypothesis of a causal
role for misfolded amyloid proteins in the disease pathogenesis, and as
a consequence, the number of trials investigating alternative disease
mechanisms and pathways are increasing.43,44 AMYPAD understands
that the accumulation of amyloid plaques is a necessary but not
sufficient step in the development of Alzheimer’s dementia. Thus,
the study purposely aligns itself with cohorts that collect extensive
assessments in a pre-dementia population to enable the assessment
of a variety of risk factors and biomarker interactions and contribute
to the understanding of this complex disease, also beyond amyloid
pathology.Nonetheless, the increased availability of larger longitudinal
datasets of cognitively unimpaired subjects has already resulted in the
compilation of an initial but growing evidence on the role of amyloid
burden as a predictor of early cognitive decline, also independently
from or corrected for other factors.9,10,45 In fact, early accumulation
of amyloid plaques in specific regions of initially amyloid-negative
healthy adults has also been linked to subclinical amyloid-related
decline in episodic memory.11 Although limited, these findings support
the notion that the seemingly elusive relationship between amyloid
pathology and cognitive impairment could be more pronounced in
stages of the disease during which amyloid is driving the cascade, that
is, before clinically relevant cognitive impairment is present. AMYPAD
PNHS might be particularly equipped to shed light into such a hypoth-
esis, as the heterogeneity in the cognitive assessments available from
different cohorts create unique opportunities to explore cognitive
functioning in detail, despite the resulting analytical challenges.
Finally, the intrinsic collaboration between AMYPAD PNHS and
several parent cohorts results in an efficient recruitment strategy,
as the operational teams are able to leverage the available historical
information on subject characteristics to ensure a targeted inclusion
process. Further, AMYPADPNHS does not burden de novo participants
because it builds on established cohorts and establishes a frame-
work that benefits all parties. While the PCs provide demographic
and extensive cognitive and biomarker data, the amyloid PET data
collected under AMYPAD’s umbrella is returned to each PC, assisting
them in reaching their own original objectives.
7 CONCLUSION
AMYPAD PNHS is a large-scale amyloid PET study established to
complement the phenotyping of longitudinal cohorts across Europe to
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better understand the value of the technique in assessing an individ-
ual’s risk of AD-related progression. The project focuses on providing
high-quality (semi-)quantitative information on amyloid burden while
leveraging extensive additional information collected in a number of
parent cohorts. The study is set to run until late 2021, after which the
data will bemade openly available to the scientific community.
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